Spaltudaq -- which may have had the hardest name to pronounce in the history of Seattle startups -- has changed its name to Theraclone Sciences. More importantly, the biotech company announced today new research that could be used to "reverse engineer" a vaccine for HIV.
Theraclone is looking to use the neutralizing effects of monoclonal antibodies from patients who have a slow progression of the disease. "Sera from such patient samples often have the ability to neutralize a broad range of HIV viruses, suggesting the possibility of antibodies capable of controlling HIV infection and progression," the company wrote in a release.
A product of the Seattle biotech incubator Accelerator, Theraclone raised $29 million in venture funding in 2007. Its backers include ARCH Venture Partners, Canaan Partners and Healthcare Ventures.
When the company started, it was looking at developing therapeutic antibodies for cancer.
READ MORE and COMMENT
No comments:
Post a Comment